Jacobs Levy Equity Management Inc. Sells 663,410 Shares of Acelyrin, Inc. (NASDAQ:SLRN)

Jacobs Levy Equity Management Inc. cut its stake in shares of Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 50.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 662,981 shares of the company's stock after selling 663,410 shares during the quarter. Jacobs Levy Equity Management Inc. owned about 0.66% of Acelyrin worth $2,082,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. T. Rowe Price Investment Management Inc. raised its position in Acelyrin by 23.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 12,872,124 shares of the company's stock worth $40,419,000 after buying an additional 2,440,278 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Acelyrin by 3.5% in the fourth quarter. Geode Capital Management LLC now owns 1,709,086 shares of the company's stock worth $5,368,000 after acquiring an additional 57,472 shares during the period. Alyeska Investment Group L.P. purchased a new position in shares of Acelyrin during the fourth quarter valued at approximately $4,760,000. Northern Trust Corp lifted its position in Acelyrin by 3.8% during the fourth quarter. Northern Trust Corp now owns 630,051 shares of the company's stock valued at $1,978,000 after purchasing an additional 23,130 shares during the period. Finally, ADAR1 Capital Management LLC boosted its holdings in Acelyrin by 731.7% in the fourth quarter. ADAR1 Capital Management LLC now owns 444,967 shares of the company's stock worth $1,397,000 after purchasing an additional 391,467 shares during the last quarter. Hedge funds and other institutional investors own 87.31% of the company's stock.

Acelyrin Trading Down 0.9%

NASDAQ:SLRN traded down $0.02 during trading hours on Monday, reaching $2.23. The company had a trading volume of 1,429,323 shares, compared to its average volume of 1,221,771. The firm has a market cap of $225.13 million, a price-to-earnings ratio of -0.91 and a beta of 1.07. The firm's 50 day moving average price is $2.41 and its 200-day moving average price is $2.96. Acelyrin, Inc. has a 52 week low of $1.85 and a 52 week high of $7.25.

Acelyrin (NASDAQ:SLRN - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.95) by $0.40. On average, analysts forecast that Acelyrin, Inc. will post -2.53 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Mina Kim sold 17,986 shares of the firm's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $2.74, for a total value of $49,281.64. Following the transaction, the chief executive officer now directly owns 671,753 shares of the company's stock, valued at approximately $1,840,603.22. This trade represents a 2.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 13.60% of the company's stock.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.